Ron Wyden

Report says Sovaldi drug maker Gilead was focused on profits, not patients

The makers of a breakthrough drug for hepatitis C put profits before patients in pricing the $1,000 pill that cures the liver-wasting disease, Senate investigators said Tuesday.

A bipartisan report from the Senate Finance Committee concluded that California-based Gilead Sciences was focused on maximizing revenue even as the company's own analysis showed a lower price would allow more patients to be treated. There was no immediate response from Gilead.

The company's first breakthrough pill was called Sovaldi; priced at $1,000 per pill, or $84,000 for a full course of treatment. Gilead has since introduced a more expensive next-generation pill called Harvoni, which is highly...